Lv3
270 积分 2021-06-08 加入
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of DualERBB2Blockade in Patients WithERBB2-Positive Breast Cancer
14小时前
已完结
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
1个月前
已完结
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
1个月前
已完结
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
1个月前
已完结
Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: Primary results from PALOMA-4
1个月前
已完结
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3
1个月前
已完结
Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer
1个月前
已完结
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial
1个月前
已完结
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
1个月前
已完结
Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial
1个月前
已完结
皖公网安备34019202002308
